David Brindley
David is an international thought-leader in the translation of life-science innovations into commercially viable products and services. His expertise spans the ‘Valley of Death,’ encompassing regulation, basic science, process engineering and finance. This distinctive skill set positions David at the forefront of socially responsible investments – in particular initiatives that make impactful contributions to global health. David currently holds a joint appointment between the University of Oxford and the Harvard Stem Cell Institute and is an active Fellow of the Royal Institution of Great Britain and the Royal Society for the Advancement of Arts and Manufacturing. In addition to being an Editorial Board member of a range of international academic and industrial journals, David is also a founder of Translation Ventures, a boutique consultancy that is actively engaged in maximizing the financial and societal value realized from cutting edge scientific innovations. Disclosure: David A Brindley has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in any postings apart from those disclosed. D.A.B. is subject to the CFA Institute’s Codes, Standards, and Guidelines, and as such, the author must stress that his contributions to this site are provided for academic interest only and must not be construed in any way as an investment recommendation.
Posts by: David
“The process must go on”: ISSCR 2013
. The sheer scale of ISSCR 2013, which has attracted almost four thousand delegates, and the proficiency with which it is run, is a major achievement by its organizer and lead sponsor: the International Society for Stem Cell Research and the Harvard Stem Cell Institute respectively. Although some organizational calamities will have almost certainly occurred, […]
Overcoming the “blood-clinic barrier”: ISSCR 2013
. Irrespective of scientific discipline, everyone is aware of the blood-brain barrier. Since its proposal in 1900 by Max Lewandowsky, and later confirmation of its discovery in the 1960s – facilitated by the advancement of the scanning electron microscope – it has gripped physiologists and contributed to significant advancements in our understanding of pharmacokinetics. However, […]
The eve of a cell therapy Grand Slam: ISSCR 2013
. Every pursuit has its headline events: business has Davos, cinematography has the Oscars and tennis has Grand Slams. These are affairs where the world’s elite gathers to reflect on achievements, and through a delicate mix of competition and collaboration, seek to drive sustained improvements in their respective fields. To extend the tennis analogy, cell […]
Clinical trials: a valid or fallacious metric of industry progress?
. Part 5 in Cell Therapy Industry 2027 series A short time ago, I had the immense pleasure of driving through the Napa Valley bathed in a warm pastel sunset. The view was accompanied by a two-chord soundtrack: the reassuring chinking of several bottles of the region’s finest and an American radio show discussing scientific […]
Life and death: The human face of the cell therapy industry
. Within the past few weeks, we have all lost someone who has impacted our lives. And this I can guarantee. On Monday 8th April 2013, I woke up, grabbed my tennis bag and headed for a morning hit. In the car, I heard the lacquered voice of the BBC’s John Humphrys report the death […]